N-Tosyl-5-bromo-4,7-diazaindole Struktur

N-Tosyl-5-bromo-4,7-diazaindole

Bezeichnung:N-Tosyl-5-bromo-4,7-diazaindole

CAS-Nr1201186-54-0

Englisch Name:N-Tosyl-5-bromo-4,7-diazaindole

CBNumberCB62470216

SummenformelC13H10BrN3O2S

Molgewicht352.21

MOL-Datei1201186-54-0.mol

N-Tosyl-5-bromo-4,7-diazaindole physikalisch-chemischer Eigenschaften

Siedepunkt	499.6±55.0 °C(Predicted)
Dichte	1.68±0.1 g/cm3(Predicted)
storage temp.	under inert gas (nitrogen or Argon) at 2-8°C
pka	-2.22±0.30(Predicted)

Gefahreninformationscode (GHS)

N-Tosyl-5-bromo-4,7-diazaindole Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
N-Tosyl-5-bromo-4,7-diazaindole is an intermediate of upadacitinib, known asupadacitinib intermediate, or upadacitinib impurity 2. As an inhibitor of Janus kinase1, upadacitinib selectively inhibits Janus kinase1 for immune system diseases such as psoriatic arthritis, rheumatoid arthritis, and Crohn's disease^[1-3].
synthetische
A solution of anhydrous DMF (272 mL) dissolved with 2-bromo-5H-pyrrolo[2,3-b]pyrazine (78.0 g, 394 mmol) was configured. The temperature is maintained at 0-5 °C (within which the subsequent reaction has been maintained), and the solution was droppedly added to the sodium (12.8 g, 532 mmol) anhydrous DMF (543 mL) suspension in the stirred state within 60 minutes. The solution turned brown and the reaction solution was stirred for about 30 min. Then, within 60 minutes, anhydrous DMF (272 mL) dissolved with p-toluenesulfonyl chloride (94.0 g, 492 mmol) was added. After stirring the mixed solution for about 1 h, it was heated to ambient temperature and stirred for about 18 h. Slowly pour the reaction mixture into ice water (6 L) and added 2.5 N NaOH in water (50.0 mL, 125 mmol). Filter the sediment to collect and stirred 3 times with cold water (200 mL). Finally, the collected products were filtered and dried to a constant weight in a vacuum oven at about 55 °C to obtain N-Tosyl-5-bromo-4,7-diazaindole (134.6 g, 97%).
Sicherheit(Safety)
N-Tosyl-5-bromo-4,7-diazaindole can cause skin irritation, severe eye irritation, and possibly respiratory irritation.
Einzelnachweise
[1] Yael Ross, Marina Magrey, Use of upadacitinib in the treatment of psoriatic arthritis, Immunotherapy, 2021, 13.
[2] Lina Serhal, Christopher J Edwards, Upadacitinib for the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 2018, 15,13-25.
[3] Eleni Kotsiliti, Upadacitinib therapy for Crohn’s disease, Nature Reviews Gastroenterology & Hepatology, 2023, 20, 483.

N-Tosyl-5-bromo-4,7-diazaindole Upstream-Materialien And Downstream Produkte

N-Tosyl-5-bromo-4,7-diazaindole Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy